Compare BioNano Genomics Inc (BNGO) vs General Dynamics Corporation (GD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs General Dynamics Corporation — how do they compare? BioNano Genomics Inc trades at $1.2 (market cap $13.66M), while General Dynamics Corporation trades at $393.25 (market cap $106.03B). The key difference: General Dynamics Corporation is far larger — about 7762.1× BioNano Genomics Inc's market cap, and General Dynamics Corporation pays a 1.62% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | GD | |
|---|---|---|
Market Cap | $13.66M | $106.03B |
Sector | Health | Industrials |
52-Week High | $4.92 | $395.97 |
52-Week Low | $1.06 | $312.53 |
Enterprise Value | $16.26M | $111.17B |
Dividend Yield | — | 1.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
General Dynamics (GD) trades at $392.68, down 0.83% on the day, amid strong fundamental performance with Q2 2026 EPS beating estimates at $4.24 versus $3.96 expected. The stock shows bullish technical signals with moving averages supporting upward momentum, while fundamentals reveal robust revenue growth to $52.55 billion in 2025 and improving profit margins. Recent contract wins including a $29.5 billion submarine award and a $1.3 billion cybersecurity contract highlight ongoing defense sector strength.
The outlook remains positive with analyst consensus pointing to 8.7% upside to the $427.40 price target, though valuation multiples appear elevated. Key risks include defense budget uncertainties and competitive pressures, while institutional sentiment remains bullish with 57% buy ratings. The company's strong backlog of $136.5 billion provides visibility for future growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →
